A5044481391- Economic and Financial Impacts of Cancer
- Glioma Diagnosis and Treatment
- Multiple and Secondary Primary Cancers
- Brain Metastases and Treatment
- Colorectal Cancer Screening and Detection
- Esophageal Cancer Research and Treatment
- Global Cancer Incidence and Screening
- Advanced MRI Techniques and Applications
- Bladder and Urothelial Cancer Treatments
- Cancer Genomics and Diagnostics
- Colorectal and Anal Carcinomas
- Glutathione Transferases and Polymorphisms
- Health Systems, Economic Evaluations, Quality of Life
- Genetic factors in colorectal cancer
- Childhood Cancer Survivors' Quality of Life
- Acute Lymphoblastic Leukemia research
- Nonmelanoma Skin Cancer Studies
- Gastrointestinal disorders and treatments
- Lymphoma Diagnosis and Treatment
- Gastric Cancer Management and Outcomes
- Radiopharmaceutical Chemistry and Applications
- Neuroblastoma Research and Treatments
- Medical Imaging and Pathology Studies
- Medical Coding and Health Information
- Breast Cancer Treatment Studies
National Cancer Institute
2014-2024
Cancer Institute (WIA)
2022
Accurate estimates of cancer survival are important for assessing optimal patient care and prognosis. Evaluation these via relative (a ratio observed expected rates) requires a population life table that is matched to the by age, sex, race and/or ethnicity, socioeconomic status, ideally risk factors under examination. Because tables all subgroups in study may be unavailable, we investigated whether cause-specific could used as an alternative survival.We data from Surveillance, Epidemiology,...
Selected molecular biomarkers were incorporated into the US cancer registry reporting for patients with brain tumors beginning in 2018. We investigated completeness and validity of these variables described epidemiology molecularly defined tumor types.
The incidence of gastrointestinal stromal tumors (GISTs) increased after the implementation GIST-specific histology coding in 2001, but updated data on trends and survival are lacking.
The objectives of this article are to assess the completeness data collected on site-specific factors (SSFs) as a part Collaborative Stage (CS) version 2 and impact transition from American Joint Committee Cancer's (AJCC) 6th 7th edition guidelines stage distribution.Incidence for melanomas skin 18 Surveillance, Epidemiology, End Results (SEER) registries (SEER-18) were analyzed. Percentages unknown cases 7 SSFs examined, along with staging trends 2004 2010 differences in AJCC distributions...
There are over 100 histologically distinct types of primary malignant and nonmalignant brain other central nervous system (CNS) tumors. Our study presents recent trends in the incidence these tumors using an updated histology recode that incorporates major diagnostic categories listed 2016 World Health Organization Classification Tumours CNS.We used data from SEER-21 registries for patients all ages diagnosed 2000-2017. We calculated age-adjusted rates fitted a joinpoint regression to...
Abstract Background: Stage is the most important prognostic factor for understanding cancer survival trends. Summary stage (SS) classifies based on extent of spread: In situ, Localized, Regional, or Distant. Continual updating staging systems poses challenges to comparisons over time. We use a consistent summary classification and present trends 25 sites using joinpoint (JPSurv) model. Methods: developed modified variable, Long-Term Site-Specific Stage, as definition possible applied it...
Although incidence rates of hepatocellular carcinoma (HCC) began to decline in the United States past decade, disparities among racial/ethnic groups have persisted. Whether stage at diagnosis remained over time, however, is unclear.National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) program has created a new staging-over-time variable that facilitates examination trends HCC stage. Thus, proportions HCCs diagnosed by between 1992 2019 were examined non-Hispanic...
<div>AbstractBackground:<p>Stage is the most important prognostic factor for understanding cancer survival trends. Summary stage (SS) classifies based on extent of spread: <i>In situ</i>, Localized, Regional, or Distant. Continual updating staging systems poses challenges to comparisons over time. We use a consistent summary classification and present trends 25 sites using joinpoint (JPSurv) model.</p>Methods:<p>We developed modified variable, Long-Term...
<p>Cancers of the anus, bladder, bone, salivary gland, vagina, and vulva: trends in five-year relative survival (SEER 8, 1975–2018, A–F) age-adjusted incidence 1975–2019) mortality (U.S., rates (G–L) by long-term summary stage (survival only). Dots represent observed lines modeled rates. Incidence are plotted on log scale.</p>
<p>Cancers of the anus, bladder, bone, salivary gland, vagina, and vulva: trends in five-year relative survival (SEER 8, 1975–2018, A–F) age-adjusted incidence 1975–2019) mortality (U.S., rates (G–L) by long-term summary stage (survival only). Dots represent observed lines modeled rates. Incidence are plotted on log scale.</p>
<div>AbstractBackground:<p>Stage is the most important prognostic factor for understanding cancer survival trends. Summary stage (SS) classifies based on extent of spread: <i>In situ</i>, Localized, Regional, or Distant. Continual updating staging systems poses challenges to comparisons over time. We use a consistent summary classification and present trends 25 sites using joinpoint (JPSurv) model.</p>Methods:<p>We developed modified variable, Long-Term...